<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955315</url>
  </required_header>
  <id_info>
    <org_study_id>DGX-J01</org_study_id>
    <nct_id>NCT03955315</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration</brief_title>
  <official_title>A Randomized, Double Blind, Sham-controlled, Multi-center Phase I / II Clinical Study to Assess the Safety and Efficacy of IDCT in Patients With Lumbar Degenerative Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiscGenics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiscGenics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and preliminary efficacy of intradiscal
      injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and one sham
      control in subjects with chronic low back pain due to Degenerative Disc Disease (DDD) at one
      lumbar level from L3 to S1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, randomized, double‑blind, sham-controlled, parallel‑group, multi-center
      study in subjects with single‑level, symptomatic lumbar intervertebral disc degeneration (&gt;6
      months) and unresponsive to conservative therapy for at least 3 months. The study will
      compare single intradiscal injections of high and low dose IDCT with one sham control group.

      6 study visits will be completed by all subjects; screening, day 1 (injection day), week 4,
      week 12, week 26 and week 52. The subject will be assessed for safety and efficacy utilizing
      VAS, ODI and JOABPEQ questionnaires alongside radiographic evaluations. The study will have a
      6 month follow-up and a 6 month extension period (total 1 year).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by number of Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the safety and tolerability of a single injection of IDCT in subjects with single‑level, symptomatic early to moderate lumbar intervertebral disc degeneration as measured by the incidence of AEs and SAEs observed from Day 1 to week 52</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Pain): Visual Analogue Scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the effect of IDCT on pain as measured by a 0-100mm Visual Analogue Scale (VAS). 0: no pain, 100: worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the effect of IDCT on disability as measured by the Oswestry Disability Index (ODI). Score of 0%: no disability, score of 100%: severely disabled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Pain): JOABPEQ</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the effect of IDCT on pain as measured by JOABPEQ. The range of the score for each domain is from 0 to 100, with higher scores indicating a better condition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radiographic Assessments</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate morphologic changes of treated intervertebral discs using MRI &amp; X-Ray assessments.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with High Dose IDCT (9M cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intradiscal injection with Low Dose IDCT (3M cells).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham needle puncture (outside disc)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IDCT</intervention_name>
    <description>Discogenic Cells + Sodium Hyaluronate Vehicle</description>
    <arm_group_label>High Dose IDCT</arm_group_label>
    <arm_group_label>Low Dose IDCT</arm_group_label>
    <other_name>Injectable Disc Cell Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Needle puncture under the muscular layer in front of the intervertebral disc</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of early to moderate degenerative disc disease (DDD), Modified Pfirrmann
             Grade 3-7.

          -  Chronic low‑back pain for at least 6 months prior to screening; unresponsive to at
             least 3 months of conservative care.

          -  Low‑back pain of 40 to 90 mm on the VAS

          -  ODI score of 30 to 90.

        Exclusion Criteria:

          -  Symptomatic involvement of more than one lumbar disc.

          -  Other persistent pain/nerve issues including, for example, radiculopathy, leg pain,
             Cauda Equine syndrome, etc.

          -  Fracture of the spine, previous lumbar spine surgery or previous treatment of the
             target disc.

          -  Evidence of dynamic instability on lumbar flexion‑extension radiographs.

          -  Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other
             undifferentiated spondyloarthropathy, or Type III Modic changes around the target
             disc.

          -  Clinical suspicion of a full thickness annular tear at the target disc or other
             abnormal disc morphology.

          -  Subjects who test positive for communicable disease, have significant systemic
             disease, or are prone to infection.

          -  Patients who are deemed unsuitable for clinical study participation by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Simpson</last_name>
    <phone>8016644176</phone>
    <email>katie@discgenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Chiba Prefecture</state>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seiji Ohtori, M.D.,Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa Prefecture</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Sakai, M.D, Ph.D.</last_name>
      <phone>+81‐463-93-1121</phone>
      <email>daisakai@is.icc.u-tokai.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu city</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Akeda,, M.D.,Ph.D.</last_name>
      <phone>+81‐59-232-1111</phone>
      <email>k_akeda@clin.medic.mie-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya university hospital</name>
      <address>
        <city>Showa-ku</city>
        <state>Nagoya</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiro Imagama, M.D, Ph.D</last_name>
      <phone>+81-52-741-2111</phone>
      <email>imagama@med.nagoya-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Kaito, M.D, Ph.D</last_name>
      <phone>+81-6-6879-5111</phone>
      <email>takashikaito@ort.med.osaka-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanashi Prefecture</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirotaka Haro, M.D., Ph.D</last_name>
      <phone>+81-55-273-1111</phone>
      <email>haro@yamanashi.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

